Bio Partnering

Partnering Opportunities:

Akaal Pharma is interested in exploring partnering opportunities with pharmaceuticals and biotech corporations for late-stage clinical development (Phase 2 and 3), regulatory approval and commercial launch of its internally designed, discovered and developed small molecule drug candidates for the treatment of various inflammatory and autoimmune diseases.

Please contact us for partnering opportunities at bd@akaalpharma.com or Cell +1 (858) 925 4555 (San Diego, CA, USA) or Tel. +61 3 9479 2584 (Melbourne, Australia)

About our clinical candidates:

Akaal Pharma has internally discovered novel compounds (small molecule drug candidates) as highly potent and selective modulators of Sphingosine 1-Phosphate receptors -1 (S1P1) useful in the treatment of autoimmune and inflammatory diseases. The proprietary compounds have displayed multimodal action against inflammatory and autoimmune indications in preclinical models as oral and topical drug candidates. Akaal Pharma owns all commercialization and intellectual property (IP) rights to its internally produced IP.

Our Phase-2 clinical candidate is a First-in-class topical treatment for the psoriasis and other skin indications such as atopic dermatitis and actinic keratosis. In the Phase-1 clinical study, our lead product candidate AKP-11 has demonstrated both safety and efficacy. The plaque severity was significantly (p=0.0016) reduced by topical treatment of AKP-11. Psoriasis is a chronic disease that requires long-term treatment. Current treatment options for treating psoriasis have adverse effects.

Our oral drug candidates that are ready for commencing Phase-1 clinical studies are potential Best-in-class potent and highly selective S1P1 modulators. The oral drug candidates are directed at the treatment of autoimmune and inflammatory disease such as multiple sclerosis and ulcerative colitis, Crohn’s disease and rheumatoid arthritis. One of the major advantages of our oral drug candidates is the desirable short and reversible lymphopenia that is necessary for enhanced safety profile of S1P1 modulation based drugs.